Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PI4KA | P42356 | 3/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260809 | 0.79 | ASH1L (0.46) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL74889 | 0.78 | PDPK1 (0.53) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL289210 | 0.76 | SMN1; SMN2 (0.56) | ASH1LALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL9676001 | 0.76 | PSMB8 (0.56) | ASH1LALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2747888 | 0.76 | SMN1; SMN2 (0.52) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL1619718 | 0.76 | ASH1L (0.44) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL30003135 | 0.76 | SMN1; SMN2 (0.56) | ASH1LALDH1A1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL22993546 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MAPTSMN1; SMN2PIK3CAPI4KA | |
| Hydrochloric Acid SCHEMBL30520684 | 0.74 | SMN1; SMN2 (0.50) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL23421550 | 0.73 | ASH1L (0.42) | ASH1LALDH1A1MAPTSMN1; SMN2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| CN-102482258-B | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2014-06-25 | — | — | CN | disclosed |
| CN-102482258-A | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2012-05-30 | — | — | CN | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| CN-102186853-A | Alpha-helix mimetics for the treatment of cancer | PRISM BIOLAB CORP | 2011-09-14 | — | — | CN | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ASH1L 2108/4885ALDH1A1 1511/4885MAPT 1638/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ASH1L 2108/4885ALDH1A1 1511/4885MAPT 1638/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | ASH1L 2108/4885ALDH1A1 1511/4885MAPT 1638/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | ASH1L 1445/4885ALDH1A1 1264/4885MAPT 2160/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | ASH1L 2108/4885ALDH1A1 1511/4885MAPT 1638/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | ASH1L 405/4885ALDH1A1 2753/4885MAPT 2270/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | ASH1L 405/4885ALDH1A1 2753/4885MAPT 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.